The UK’s National Institute for Health and Care Excellence (NICE) is undertaking an exploratory study on how patient preferences could be captured and included in Health Technology Assessments (HTA).
Funded by a £120,000 health services research grant from UK charity Myeloma UK, the study aims to improve the way patient perspectives are taken into consideration and used to inform decisions about the availability of new treatments.
Decisions by HTA bodies such as NICE have a large impact in determining which treatments patients and their clinicians have access to. However, there is no agreement about how best to use patient’s perspectives with other types of evidence calculated in the cost of new treatments.
The study will analyse the best methods in capturing information about patient preferences relating to their condition and treatments. It will be undertaken in consultation with patient groups, experts and other leading HTA bodies across the world.